title: A systematic review of treatment guidelines for metastatic colorectal cancer.
abstract: OBJECTIVE
  A systematic review of treatment guidelines for metastatic colorectal cancer (mCRC) was performed to assess recommendations for monoclonal antibody therapy in these guidelines.
  
  
  METHODS
  Relevant papers were identified through electronic searches of MEDLINE, MEDLINE In Process, EMBASE and the Cochrane Library; through manual searches of reference lists; and by searching the Internet.
  
  
  RESULTS
  A total of 57 relevant guidelines were identified, 32 through electronic database searches and 25 through the website searches. The majority of guidelines were published between 2004 and 2010. The country publishing the most guidelines was the USA (12), followed by the UK (10), Canada (eight), France (eight), Germany (three), Australia (two), Spain (two) and Italy (one). In addition, eight European and three international guidelines were identified. As monoclonal antibody therapy for mCRC was not introduced until 2004, no firm recommendations for monoclonal antibody therapy were made in guidelines published between 2004 and 2006. Recommendations for monoclonal antibody therapy first appeared in 2007 and evolved as more data became available. The most recent international, European and US guidelines recommend combination chemotherapy with the addition of a monoclonal antibody for the first-line treatment of mCRC. Second-line treatment depends on the first-line regimen used. For chemoresistant mCRC, cetuximab or panitumumab are recommended as monotherapy in patients with wild-type KRAS tumours.
  
  
  CONCLUSIONS
  The study indicates that recent treatment guidelines have recognized the role of monoclonal antibodies in the management of mCRC, and that treatment guidelines should be updated in a timely manner to reflect the most recently available data.
authors.affiliation: PRMA Consulting Ltd, Centaur House, Ancells Business Park, Hampshire, UK. medwards@prmaconsulting.com
authors.forename: M S
authors.initials: MS
authors.lastname: Edwards
authors.forename: S D
authors.initials: SD
authors.lastname: Chadda
authors.forename: Z
authors.initials: Z
authors.lastname: Zhao
authors.forename: B L
authors.initials: BL
authors.lastname: Barber
authors.forename: D P
authors.initials: DP
authors.lastname: Sykes
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000068258:Bevacizumab; D000068818:Cetuximab; D015179:Colorectal Neoplasms / Q000188:drug therapy*; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D000077544:Panitumumab; D017410:Practice Guidelines as Topic
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007155:Immunologic Factors; D000068258:Bevacizumab; D000077544:Panitumumab; D000068818:Cetuximab